Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Acquires IDbyDNA

NEW YORK – Illumina has acquired IDbyDNA, a company developing metagenomic technology for infectious disease testing and pathogen surveillance, GenomeWeb has learned today.

The firms have had an alliance for the past two years comarketing IDbyDNA's Explify platform for use with Illumina's NGS instruments and library preparation kits. They also were codeveloping research-use-only workflows.

The partners offer a respiratory pathogen panel enrichment kit that identifies more than 280 pathogens, including SARS-CoV-2, and more than 1,200 antimicrobial resistance alleles. It runs on Illumina’s NextSeq 550 sequencing system and utilizes IDbyDNA’s Explify analysis software.

Illumina didn’t respond by press time to a request for comment. The deal was confirmed by a former executive of IDbyDNA, a University of Utah spinout.

As part of the deal, IDbyDNA Cofounder and Chief Medical Officer Robert Schlaberg has joined Illumina as distinguished scientist, infectious disease and VP. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.